Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA2 | P54646 | 3/20 | 0.43 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.43 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.43 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.43 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.43 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.43 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14077856 | 1.00 | PRKAA2 (0.43) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL14078587 | 0.92 | L3MBTL1 (0.47) | KDM4EMEN1TSHRKMT2APOLB | |
| SCHEMBL13392067 | 0.92 | L3MBTL1 (0.47) | KDM4EMEN1TSHRKMT2APOLB | |
| SCHEMBL13392079 | 0.91 | PRKAA2 (0.47) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL14188215 | 0.91 | PRKAA2 (0.47) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL13391020 | 0.91 | ALDH1A1 (0.44) | CYP3A4KDM4EMEN1TSHRKMT2A | |
| SCHEMBL14188214 | 0.91 | KMT2A (0.49) | KDM4EMEN1TSHRKMT2APOLB | |
| SCHEMBL13392059 | 0.91 | KMT2A (0.49) | KDM4EMEN1TSHRKMT2APOLB | |
| SCHEMBL13392099 | 0.90 | PRKAA2 (0.47) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL14078053 | 0.90 | PRKAA2 (0.47) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093692-A1 | PIPERIDINYL-PIPERIDINE AND PIPERAZINYL-PIPERIDINE FOR USE IN THE TREATMENT OF DIABETES OR PAIN | SCHERING CORPORATION SECHERING-PLOUGH CORPORATION (US) | 2010-04-15 | — | — | US | disclosed |
| US-7300941-B2 | Non-imidazole compounds | SCHERING CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093692-A1 | PIPERIDINYL-PIPERIDINE AND PIPERAZINYL-PIPERIDINE FOR USE IN THE TREATMENT OF DIABETES OR PAIN | GPR119, ATF4, GID4 | PRKAA2 1437/4885PRKAB2 426/4885PRKAG1 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.